MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $25 (last qtr, 8 analysts) → $25 (last mo, 3) (-3.7%).
Buy-rated share 32% → 32% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $0.99 | $1.07 | +8.5% |
| Jul 2026 | $0.97 | $1.04 | +7.7% |
| Apr 2026 | $0.72 | $0.79 | +9.0% |
| Jan 2026 | $0.73 | $0.84 | +15.2% |
| Oct 2025 | $1.03 | $1.12 | +8.7% |
| Jul 2025 | $1.16 | $1.25 | +7.8% |
| Apr 2025 | $0.99 | $1.09 | +10.4% |
| Jan 2025 | $0.86 | $0.96 | +11.4% |
No recent open-market insider transactions.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $116.4B— | $121.4B+4.3% | $121.6B+0.1% | $123.7B+1.8% | $123.7B-0.0% |
| EPS (dil.) | $3.04— | $1.21-60.2% | $3.71+206.6% | $4.14+11.6% | $5.39+30.2% |
| Free Cash Flow | $17.1B— | $12.6B-26.0% | $13.0B+2.5% | $15.4B+18.6% | $19.2B+25.1% |
| Gross Margin | 67.0% | 68.5%+1.6pp | 69.8%+1.2pp | 70.1%+0.3pp | 71.7%+1.7pp |
| Operating Margin | 17.9% | 18.6%+0.7pp | 19.2%+0.5pp | 18.8%-0.3pp | 16.7%-2.1pp |
| Net Margin | 12.2% | 4.4%-7.7pp | 12.7%+8.2pp | 13.1%+0.4pp | 16.2%+3.1pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 0.6%/yr (revenue basis).
Base free cash flow $15.9B (avg FY2023–FY2025; latest year $19.2B) · equity value $81.7B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 53 for CMCSA suggests a neutral outlook, with the stock's value and profitability scores driving it up, while growth and momentum scores pull it down. CMCSA scores high on value, trading at a P/E of 7.3 and exhibiting strong profitability with an ROE of 12.3%. In contrast, its growth score is lower due to flat revenue growth, and momentum is weak with a 12-month return of -18.6%. The long-term and short-term scores are relatively aligned, indicating a consistent view of the stock's fundamentals.